azelaic acid 15% gel

DRUG7 trials

Sponsors

LEO Pharma, Galderma R&D

Conditions

Papulopustular RosaceaPapulopustular Rosacea (PPR)Perioral DermatitisSeborrheic Dermatitis on the FaceSkin Manifestations

Phase 2

A Study of Azelaic Acid (AzA) 15% in Topical Treatment of Mild to Moderate Perioral Dermatitis

CompletedNCT00403949

LEO PharmaPerioral Dermatitis

Start: 2006-11-30End: 2007-03-31Updated: 2023-06-09

A Study of Azelaic Acid (AzA) 15% Gel in the Treatment of Seborrheic Dermatitis of the Face

CompletedNCT00408330

LEO PharmaSeborrheic Dermatitis on the Face

Start: 2006-12-31End: 2007-03-31Updated: 2023-06-09

Phase 3

Phase 3 Papulopustular Rosacea Study

CompletedNCT01493687

Galderma R&DPapulopustular Rosacea (PPR)

Start: 2011-12-31End: 2013-08-31Updated: 2021-02-18

Phase 3 Papulopustular Rosacea Study

CompletedNCT01494467

Galderma R&DPapulopustular Rosacea

Start: 2011-12-31End: 2013-08-31Updated: 2021-02-18

Phase 4

A Multicenter Trial of a Topical Medication for Papulopustular Rosacea Applied Twice Daily Versus Once Daily

CompletedNCT00417937

LEO PharmaPapulopustular Rosacea

Start: 2007-01-31End: 2007-06-30Updated: 2023-06-09

Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin

CompletedNCT01139047

Galderma R&DSkin Manifestations

Start: 2010-06-30End: 2010-06-30Updated: 2022-08-01

Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin

CompletedNCT01139008

Galderma R&DSkin Manifestations

Start: 2010-06-30End: 2010-06-30Updated: 2022-08-01